Your browser doesn't support javascript.
loading
High False-Positive Rate of (1,3)-ß-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies.
Tschopp, Jonathan; Brunel, Anne Sophie; Spertini, Olivier; Croxatto, Anthony; Lamoth, Frederic; Bochud, Pierre Yves.
Afiliação
  • Tschopp J; Infectious Diseases Service, University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Brunel AS; Infectious Diseases Service, University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Spertini O; Hematology Service, University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Croxatto A; ADMed Microbiologie, La Chaux-de-Fonds, Switzerland.
  • Lamoth F; Infectious Diseases Service, University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Bochud PY; Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland.
Clin Infect Dis ; 75(2): 330-333, 2022 08 25.
Article em En | MEDLINE | ID: mdl-34996098
ABSTRACT
Immunoglobulins and/or therapeutic antibody preparations are associated with a high rate of false-positive (1,3)-ß-D-glucan (BDG) tests in onco-hematological patients routinely screened for fungal infections. The benefit of BDG monitoring shall be balanced against the risk of false-positive tests leading to unnecessary investigations and costs in this population.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Beta-Glucanas / Glucanos Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Beta-Glucanas / Glucanos Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article